2016 Q1 Form 10-Q Financial Statement
#000156459016017257 Filed on May 02, 2016
Income Statement
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| Revenue | $236.7M | $202.9M |
| YoY Change | 16.66% | 33.89% |
| Cost Of Revenue | $43.12M | $31.00M |
| YoY Change | 39.1% | 35.86% |
| Gross Profit | $193.6M | $171.9M |
| YoY Change | 12.62% | 33.55% |
| Gross Profit Margin | 81.79% | 84.72% |
| Selling, General & Admin | $105.3M | $92.81M |
| YoY Change | 13.46% | 54.5% |
| % of Gross Profit | 54.39% | 53.98% |
| Research & Development | $158.8M | $142.1M |
| YoY Change | 11.77% | 64.88% |
| % of Gross Profit | 82.01% | 82.64% |
| Depreciation & Amortization | $18.73M | $10.82M |
| YoY Change | 73.12% | 12.68% |
| % of Gross Profit | 9.67% | 6.29% |
| Operating Expenses | $264.1M | $234.9M |
| YoY Change | 12.44% | 60.62% |
| Operating Profit | -$80.92M | -$65.86M |
| YoY Change | 22.86% | 148.94% |
| Interest Expense | $9.843M | $9.462M |
| YoY Change | 4.03% | 3.91% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $200.0K | $200.0K |
| YoY Change | 0.0% | 0.0% |
| Pretax Income | -$89.13M | -$74.70M |
| YoY Change | 19.31% | 115.75% |
| Income Tax | -$6.075M | -$7.202M |
| % Of Pretax Income | ||
| Net Earnings | -$83.05M | -$67.50M |
| YoY Change | 23.04% | 77.1% |
| Net Earnings / Revenue | -35.08% | -33.26% |
| Basic Earnings Per Share | -$0.43 | |
| Diluted Earnings Per Share | -$514.6K | -$0.43 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 157.6M | |
| Diluted Shares Outstanding | 157.6M |
Balance Sheet
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $456.9M | $1.009B |
| YoY Change | -54.7% | 13.66% |
| Cash & Equivalents | $270.5M | $900.6M |
| Short-Term Investments | $186.4M | $108.1M |
| Other Short-Term Assets | $58.20M | $115.5M |
| YoY Change | -49.61% | 181.62% |
| Inventory | $297.0M | $222.8M |
| Prepaid Expenses | $39.16M | |
| Receivables | $180.8M | $175.7M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $992.8M | $1.523B |
| YoY Change | -34.8% | 22.17% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $725.1M | $538.1M |
| YoY Change | 34.75% | 23.12% |
| Goodwill | $148.1M | |
| YoY Change | 173.02% | |
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $314.4M | $224.8M |
| YoY Change | 39.86% | -10.76% |
| Other Assets | $260.5M | $243.7M |
| YoY Change | 6.89% | 486.59% |
| Total Long-Term Assets | $2.674B | $2.136B |
| YoY Change | 25.2% | 95.19% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $992.8M | $1.523B |
| Total Long-Term Assets | $2.674B | $2.136B |
| Total Assets | $3.667B | $3.659B |
| YoY Change | 0.23% | 56.31% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $145.9M | $23.61M |
| YoY Change | 518.06% | 54.01% |
| Accrued Expenses | $111.3M | $106.5M |
| YoY Change | 4.54% | 65.33% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $388.0M | $305.5M |
| YoY Change | 27.01% | 95.79% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $668.0M | $655.5M |
| YoY Change | 1.91% | -0.89% |
| Other Long-Term Liabilities | $177.2M | $79.00M |
| YoY Change | 124.3% | 219.58% |
| Total Long-Term Liabilities | $845.2M | $734.5M |
| YoY Change | 15.07% | 2871.28% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $388.0M | $305.5M |
| Total Long-Term Liabilities | $845.2M | $734.5M |
| Total Liabilities | $1.377B | $1.233B |
| YoY Change | 11.64% | 40.04% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $2.290B | $2.426B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $3.667B | $3.659B |
| YoY Change | 0.23% | 56.31% |
Cashflow Statement
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$83.05M | -$67.50M |
| YoY Change | 23.04% | 77.1% |
| Depreciation, Depletion And Amortization | $18.73M | $10.82M |
| YoY Change | 73.12% | 12.68% |
| Cash From Operating Activities | -$171.5M | -$137.8M |
| YoY Change | 24.46% | 412.76% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $45.20M | $43.83M |
| YoY Change | 3.13% | 85.67% |
| Acquisitions | $538.4M | |
| YoY Change | ||
| Other Investing Activities | $150.0K | $1.027M |
| YoY Change | -85.39% | -106.89% |
| Cash From Investing Activities | $77.00M | -$750.9M |
| YoY Change | -110.25% | 1820.85% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $888.3M | |
| YoY Change | 656.2% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -37.30M | 914.8M |
| YoY Change | -104.08% | 567.92% |
| NET CHANGE | ||
| Cash From Operating Activities | -171.5M | -137.8M |
| Cash From Investing Activities | 77.00M | -750.9M |
| Cash From Financing Activities | -37.30M | 914.8M |
| Net Change In Cash | -131.8M | 26.10M |
| YoY Change | -604.98% | -63.24% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$171.5M | -$137.8M |
| Capital Expenditures | $45.20M | $43.83M |
| Free Cash Flow | -$216.7M | -$181.6M |
| YoY Change | 19.31% | 259.8% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
1146000 | |
| CY2015Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
1232000 | |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
236736000 | |
| CY2016Q1 | us-gaap |
Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
|
13560000 | |
| CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
97449000 | |
| CY2016Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
388011000 | |
| CY2016Q1 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
668009000 | |
| CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
135275000 | |
| CY2016Q1 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
143527000 | |
| CY2015Q1 | us-gaap |
Revenues
Revenues
|
202920000 | |
| CY2015Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
10817000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-106128000 | |
| CY2015Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
282000 | |
| CY2015Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
130000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
26789000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-330000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-57236000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
9186000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-137811000 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
43832000 | |
| CY2015Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
124137000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
76999000 | |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
3521000 | |
| CY2016Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
40788000 | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
|
1614000 | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
56000 | |
| CY2016Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
31015000 | |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
20244000 | |
| CY2016Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
7337000 | |
| CY2015Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
7000000 | |
| CY2016Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-309000 | |
| CY2016Q1 | us-gaap |
Contracts Revenue
ContractsRevenue
|
233000 | |
| CY2015Q1 | us-gaap |
Contracts Revenue
ContractsRevenue
|
376000 | |
| CY2016Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
43118000 | |
| CY2015Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
30998000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
158793000 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
142074000 | |
| CY2016Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
105300000 | |
| CY2015Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
92806000 | |
| CY2016Q1 | bmrn |
Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
|
10442000 | |
| CY2015Q1 | bmrn |
Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
|
2902000 | |
| CY2016Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
317653000 | |
| CY2015Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
268780000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-80917000 | |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-65860000 | |
| CY2016Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-135000 | |
| CY2015Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-150000 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1571000 | |
| CY2015Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
683000 | |
| CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
9843000 | |
| CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
9462000 | |
| CY2015Q1 | us-gaap |
Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
|
163000 | |
| CY2016Q1 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
198000 | |
| CY2015Q1 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
249000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-89126000 | |
| CY2015Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-74703000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-3984000 | |
| CY2015Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-7202000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-85142000 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-67501000 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.53 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.43 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
161548000 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
157612000 | |
| CY2015Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-51148000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-20986000 | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3521000 | |
| CY2016Q1 | us-gaap |
Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
|
99000 | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
40788000 | |
| CY2015Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-417000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
30177000 | |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
22692000 | |
| CY2016Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-19277000 | |
| CY2015Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-7800000 | |
| CY2016Q1 | us-gaap |
Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
|
99000 | |
| CY2015Q1 | us-gaap |
Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
|
527000 | |
| CY2016Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
6526000 | |
| CY2015Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
5686000 | |
| CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
2936000 | |
| CY2016Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-526000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
16044000 | |
| CY2016Q1 | bmrn |
Stock Based Compensation Capitalized
StockBasedCompensationCapitalized
|
2469000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
914791000 | |
| CY2016Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
5132000 | |
| CY2015Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-1025000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-126587000 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
25084000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
875486000 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
900570000 | |
| CY2016Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
73215000 | |
| CY2015Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
1358000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
11803000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
19344000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-2399000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
3522000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
1232000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-90744000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-4614000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-171553000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
45204000 | |
| CY2016Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
181267000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
58914000 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
288431000 | |
| CY2016Q1 | us-gaap |
Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
|
150000 | |
| CY2015Q1 | us-gaap |
Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
|
3326000 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
538392000 | |
| CY2015Q1 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
1027000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-750871000 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
28026000 | |
| CY2015Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
735000 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
888257000 | |
| CY2016Q1 | us-gaap |
Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
|
99000 | |
| CY2015Q1 | us-gaap |
Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
|
527000 | |
| CY2016Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
3000 | |
| CY2015Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-1284000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-37165000 | |
| CY2015Q1 | bmrn |
Stock Based Compensation Capitalized
StockBasedCompensationCapitalized
|
2480000 | |
| CY2016Q1 | bmrn |
Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
|
2617000 | |
| CY2015Q1 | bmrn |
Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
|
3580000 | |
| CY2016Q1 | bmrn |
Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
|
-14788000 | |
| CY2015Q1 | bmrn |
Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
|
-20985000 | |
| CY2015Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
8133000 | |
| CY2016Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
|
2436000 | |
| CY2016Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) NATURE OF OPERATIONS AND BUSINESS RISKS</p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">BioMarin Pharmaceutical Inc. (the Company or BioMarin), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s product portfolio consists of five approved products and multiple clinical and pre-clinical product candidates. The Company’s approved products are Vimizim (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks, including: the financial performance of its approved products; the potential need for additional financings; the Company’s ability to successfully commercialize its approved product candidates; the uncertainty of the Company’s research and development (R&D) efforts resulting in future successful commercial products; the Company’s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry. </p></div> | |
| CY2016Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) BASIS OF PRESENTATION</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by the United States (U.S.) generally accepted accounting principles (U.S. GAAP) for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2016.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</p></div> | |
| CY2016Q1 | us-gaap |
Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
|
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) RECENT ACCOUNTING PRONOUNCEMENTS</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Except as described below, there have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended March 31, 2016, as compared to the recent accounting pronouncements described in Note 4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, that are of significance or potential significance to the Company.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, <font style="color:#000000;">the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, </font><font style="font-style:italic;color:#000000;">Improvements to Employee Share-Based Payment Accounting</font><font style="color:#000000;"> (ASU 2016-09), which is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. </font>ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early application is permitted. <font style="color:#000000;">ASU 2016-09 will be effective for the Company’s fiscal year beginning January 1, 2017 unless it elects early adoption. </font>The Company is currently evaluating the potential impact the adoption of ASU 2016-09 will have on its consolidated financial statements and has not elected to early adopt the amendments.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, <font style="color:#000000;">the FASB issued ASU No. 2016-02, </font><font style="font-style:italic;color:#000000;">Leases</font><font style="color:#000000;"> (ASU 2016-02). The amended guidance requires balance sheet recognition of lease assets and liabilities by lessees for leases classified as operating leases, with an option to not recognize lease assets and lease liabilities for leases with a term of 12 months or less. The amendments also require new disclosures providing additional qualitative and quantitative information about the amounts recorded in the financial statements. Lessor accounting is largely unchanged.</font> ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. <font style="color:#000000;">ASU 2016-02 will be effective for the Company’s fiscal year beginning January 1, 2019 unless it elects early adoption. The amendments require a modified retrospective approach with optional practical expedients. </font>The Company is currently evaluating the potential impact the adoption of ASU 2016-02 will have on its consolidated financial statements and has not elected to early adopt ASU 2016-02.<font style="color:#000000;"> </font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 (ASU 2014-09) regarding Accounting Standards Codification (ASC) Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>. ASU 2014-09 provides principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14 to defer the effective date by one year with early adoption permitted as of the original effective date. ASU 2014-09 will be effective for the Company’s fiscal year beginning January 1, 2018 unless it elects the earlier date of January 1, 2017. In March 2016, the FASB issued ASU 2016-08 to help provide interpretive clarifications on the new guidance for ASC Topic 606. In April 2016, the FASB issued ASU 2016-10 to clarify the guidance for identifying performance obligations and accounting for licenses of intellectual property. The Company is currently evaluating the accounting, transition, and disclosure requirements of the standard<font style="color:#000000;">.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p></div> | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
100000 | |
| CY2016Q1 | bmrn |
Number Of Products Approved
NumberOfProductsApproved
|
5 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22232000 | |
| CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22635000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
499545000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1448000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
189000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
622207000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
500804000 | |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
15700000 | |
| CY2015Q1 | us-gaap |
Depreciation
Depreciation
|
11500000 | |
| CY2016Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
44973000 | |
| CY2015Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
46115000 | |
| CY2016Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
163333000 | |
| CY2015Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
150289000 | |
| CY2016Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
88673000 | |
| CY2015Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
75279000 | |
| CY2015Q4 | bmrn |
Deposit For Business Acquisition
DepositForBusinessAcquisition
|
371756000 | |
| CY2016Q1 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8720000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1076000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
621231000 | |
| CY2016Q1 | bmrn |
Number Of Investments In Marketable Equity Securities
NumberOfInvestmentsInMarketableEquitySecurities
|
2 | |
| CY2016Q1 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
8100000 | |
| CY2015Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
18100000 | |
| CY2016Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
2800000 | |
| CY2015 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
12700000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
186400000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
195579000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
314404000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
425652000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
500804000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
621231000 | |
| CY2016Q1 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | |
| CY2016Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
302595000 | |
| CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
129572000 | |
| CY2016Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
935361000 | |
| CY2015Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
607548000 | |
| CY2016Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
1237956000 | |
| CY2015Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
737120000 | |
| CY2016Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
60724000 | |
| CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
53124000 | |
| CY2016Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1011033000 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
982810000 | |
| CY2016Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
294117000 | |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
278603000 | |
| CY2015Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8606000 | |
| CY2016Q1 | us-gaap |
Investments
Investments
|
8142000 | |
| CY2015Q4 | us-gaap |
Investments
Investments
|
18056000 | |
| CY2016Q1 | us-gaap |
Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
|
734000 | |
| CY2015Q4 | us-gaap |
Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
|
3533000 | |
| CY2016Q1 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
7804000 | |
| CY2015Q4 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
6693000 | |
| CY2016Q1 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
152860000 | |
| CY2015Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
179294000 | |
| CY2016Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
45031000 | |
| CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
78424000 | |
| CY2016Q1 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
34158000 | |
| CY2015Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
32553000 | |
| CY2016Q1 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
19696000 | |
| CY2015Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
16921000 | |
| CY2016Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
10787000 | |
| CY2015Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
10412000 | |
| CY2016Q1 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
10437000 | |
| CY2015Q4 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
6377000 | |
| CY2016Q1 | us-gaap |
Accrued Income Taxes
AccruedIncomeTaxes
|
1593000 | |
| CY2015Q4 | us-gaap |
Accrued Income Taxes
AccruedIncomeTaxes
|
59572000 | |
| CY2015Q4 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
8958000 | |
| CY2016Q1 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
996697000 | |
| CY2016Q1 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
16000000 | |
| CY2015Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
1147301000 | |
| CY2016Q1 | us-gaap |
Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
|
7692000 | |
| CY2016Q1 | us-gaap |
Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
|
11004000 | |
| CY2015Q4 | us-gaap |
Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
|
14011000 | |
| CY2015Q4 | us-gaap |
Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
|
5065000 | |
| CY2016Q1 | us-gaap |
Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
|
2500000 | |
| CY2015 | us-gaap |
Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
|
13600000 | |
| CY2016Q1 | us-gaap |
Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
|
250000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
715540 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
41.67 | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
0 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
30177000 | |
| CY2015Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
22692000 | |
| CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
2500000 | |
| CY2015Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
2500000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
|
-16157000 | |
| CY2016Q1 | us-gaap |
Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
|
7621000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
-2792000 | |
| CY2014Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
27466000 | |
| CY2015Q1 | us-gaap |
Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
|
25252000 | |
| CY2015Q1 | us-gaap |
Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
|
4739000 | |
| CY2015Q1 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
4160000 | |
| CY2015Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
16353000 | |
| CY2015Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
43819000 | |
| CY2016Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2016Q1 | bmrn |
Contingent Payments Upon Achievement Of Certain Regulatory And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainRegulatoryAndLicensingMilestones
|
880800000 | |
| CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
232700000 |
